文献速递淋巴瘤

比美替尼抑制MEK1/2单药有效并在模拟慢性淋巴细胞白血病肿瘤微环境条件下增强Venetoclax与ABT-737的作用

MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment.
PubMed 文献 · Br J Haematol · 2018-05-16

研究在模拟慢性淋巴细胞白血病(CLL)肿瘤微环境的培养条件下,观察MEK1/2抑制剂比美替尼对CLL细胞的作用。比美替尼阻断基质条件培养基和PMA诱导的CLL细胞存活,对anti-IgM抗体或SDF-1α条件下培养的CLL细胞毒性显著更强,并减少细胞周期进展和增殖。比美替尼还通过下调Mcl-1活性及Bim和Bcl-xL表达,显著增加与表达CD40L的成纤维细胞共培养的CLL细胞对BH3模拟物ABT-737和Venetoclax的敏感性。作者认为比美替尼对CLL细胞可能兼具细胞毒和细胞静止作用,与BH3模拟物联用可能是CLL的有效治疗策略。

要点

  • 比美替尼阻断基质条件培养基和PMA诱导的CLL细胞存活。
  • 比美替尼对anti-IgM或SDF-1α条件下培养的CLL细胞毒性显著更强,并减少细胞周期进展和增殖。
  • 比美替尼通过下调Mcl-1活性及Bim和Bcl-xL表达,增强CD40L共培养CLL细胞对ABT-737和Venetoclax的敏感性。

核心结论

  • 比美替尼可能通过阻断驱动存活和增殖的微环境来源信号,对CLL细胞兼具细胞毒和细胞静止作用。
  • 比美替尼与BH3模拟物联用可能是CLL的有效治疗策略,尤其针对肿瘤微环境中的增殖部分。

研究设计与样本

  • 体外研究:将CLL细胞在模拟肿瘤微环境部分特征的条件下培养,包括基质条件培养基、PMA、anti-IgM抗体、SDF-1α及与表达CD40L的成纤维细胞共培养。

主要发现

  • 比美替尼阻断基质条件培养基和PMA诱导的CLL细胞存活。
  • 比美替尼对anti-IgM抗体或SDF-1α条件下培养的CLL细胞毒性显著更强,并减少CLL细胞周期进展和增殖。
  • 比美替尼通过下调Mcl-1活性及Bim和Bcl-xL表达,显著增加与表达CD40L的成纤维细胞共培养的CLL细胞对ABT-737和Venetoclax的敏感性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The survival and proliferation of chronic lymphocytic leukaemia (CLL) cells is driven by multiple signalling pathways, including those mediated by the B cell, Toll-like and chemokine receptors. Many of these pathways converge on the same signalling molecules, including those involved in the Raf-1/MEK/Erk1/2-MAPK pathway. We investigated the effects of the MEK1/2 (also termed MAP2K1/2) inhibitor, binimetinib, against CLL cells cultured under conditions that mimic aspects of the tumour microenvironment. Binimetinib blocked CLL cell survival induced by stroma-conditioned media and phorbol myristylate (PMA). Binimetinib was also significantly more toxic towards CLL cells cultured in the presence of either anti-IgM antibody or stroma-derived factor-1α (SDF-1α) and reduced CLL cell cycle progression and proliferation. Furthermore, binimetinib significantly increased the sensitivity of CLL cells co-cultured with CD40 ligand (CD40L)-expressing fibroblasts to the BH3-mimetics ABT-737 and Venetoclax (ABT-199) via a mechanism involving down-regulation of Mcl-1 (MCL1) activity and Bim (BCL2L11) and Bcl-xL (BCL2L1) expression. Collectively, these data suggest that binimetinib may have both cytotoxic and cytostatic effects on CLL cells by blocking microenvironment-derived signals known to drive survival and proliferation. The combination of binimetinib with a BH3 mimetic may be an effective treatment strategy for CLL, particularly against the proliferative fraction of the disease within the tumour microenvironment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Crassini K, Shen Y, Stevenson WS, et al. MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment. Br J Haematol. 2018. PMID: 29767411. doi:10.1111/bjh.15282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。